Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATIVAN vs CHLORDIAZACHEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Chlordiazepoxide is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion influx, hyperpolarization of neurons, and decreased neuronal excitability. This produces anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects.
Anxiety disorders,Short-term relief of anxiety symptoms,Status epilepticus (IV),Preanesthetic medication (IM/IV)
Anxiety disorders,Acute alcohol withdrawal,Preoperative anxiety,Irritable bowel syndrome (off-label),Panic disorder (off-label)
2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.
Initial: 5-10 mg orally 3-4 times daily; for severe anxiety, up to 25 mg 4 times daily. IM: 50-100 mg initially, then 25-50 mg 3-4 times daily if needed.
Terminal elimination half-life is 12–18 hours (mean ~14 h). In elderly, hepatic impairment, or obesity, half-life may be prolonged up to 30 hours.
Parent: 5-30 hours (mean 15 hours); active metabolite desmethylchlordiazepoxide: 10-20 hours; further metabolite demoxepam: 24-96 hours; clinical context: causes drug accumulation with chronic dosing, especially in elderly or hepatic impairment.
Hepatic via glucuronidation (UGT2B15, UGT2B7); major metabolite is lorazepam glucuronide (inactive).
Chlordiazepoxide is metabolized in the liver primarily by CYP3A4 and CYP2D6 enzymes. Its active metabolites include desmethylchlordiazepoxide, demoxepam, and nordazepam.
Renal: lorazepam is primarily excreted as inactive glucuronide conjugates; <1% is excreted unchanged. Total: ~95% excreted in urine, ~5% in feces.
Renal: 50-70% as metabolites (mainly oxazepam and desmethylchlordiazepoxide); biliary/fecal: 10-20% as glucuronide conjugates; 1-2% excreted unchanged.
91% ± 2% bound to albumin. Binding is linear over therapeutic concentrations and not saturable.
90-98% bound to albumin and alpha-1-acid glycoprotein.
1.3 ± 0.2 L/kg. Vd increases with obesity, hepatic cirrhosis, and in elderly patients, indicating extensive tissue distribution.
0.5-0.8 L/kg; high Vd indicates extensive tissue distribution, with accumulation in adipose and brain tissue.
Oral: 90% (range 80–100%) with first-pass metabolism negligible; Sublingual: ~90%; Intramuscular: 100% (absolute bioavailability).
Oral: 90-100% (well absorbed); IM: 80-100% (but variable due to precipitation at injection site); IV: 100%.
Cr Cl 10-50 m L/min: reduce dose by 50% or increase interval; Cr Cl <10 m L/min: avoid or reduce dose by 50-75% with caution.
GFR 10-50 m L/min: administer 50-100% of usual dose; GFR <10 m L/min: administer 25-50% of usual dose.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or reduce dose by 50-75% with monitoring.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce by 75%.
Children ≥6 months: 0.02-0.05 mg/kg/dose IV/IM (max 2 mg) for status epilepticus; PO: 0.05-0.1 mg/kg/dose (max 2 mg) 2-4 times daily.
Children 6-12 years: 5 mg orally 2-4 times daily, max 30 mg/day. Not recommended under 6 years.
Initiate at 0.5-1 mg orally daily in divided doses; increase slowly; max 2 mg/day. IV/IM: 0.5-1 mg initial; avoid doses >2 mg due to increased sedation risk.
Initial: 5 mg orally 1-2 times daily, increase cautiously; reduce total daily dose by 50% compared to younger adults.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
Respiratory depression risk,Dependence and withdrawal syndrome,Abuse potential,Paradoxical reactions (hyperactivity, aggression),Use with caution in hepatic impairment,Elderly at increased risk for sedation and falls
Risk of dependence and withdrawal reactions,Potential for abuse and addiction,Respiratory depression, especially with concomitant CNS depressants,Central nervous system depressant effects, caution with impaired hepatic or renal function,Paradoxical reactions (e.g., agitation, aggression) in psychiatric patients,Suicidal ideation and behavior,Use in pregnancy: risk of neonatal sedation and withdrawal,Elderly patients: increased sensitivity and risk of falls
Hypersensitivity to lorazepam or any benzodiazepine,Acute narrow-angle glaucoma,Severe respiratory insufficiency,Myasthenia gravis,Concurrent use with opioids (absolute unless alternative unavailable)
Hypersensitivity to chlordiazepoxide or any benzodiazepine,Severe respiratory insufficiency,Sleep apnea syndrome,Severe hepatic impairment,Myasthenia gravis,Acute narrow-angle glaucoma,Concomitant use with ketoconazole, itraconazole, or other strong CYP3A4 inhibitors
No specific food interactions. However, grapefruit juice may increase lorazepam levels (minor interaction). Avoid excessive caffeine as it may reduce sedative effects.
Avoid alcohol. No specific food interactions; take with or without food. Limit caffeine if it worsens symptoms.
First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avoid in first trimester if possible; use lowest effective dose.
First trimester: Increased risk of cleft lip/palate (OR 1.8-2.5). Second/third trimester: Risk of neonatal withdrawal, hypotonia, respiratory depression. Avoid in pregnancy unless benefit justifies risk.
Enters breast milk; M/P ratio approximately 0.2–0.5; avoid or use with caution due to infant sedation and feeding difficulties; monitor for drowsiness and weight gain.
Excreted in breast milk; M/P ratio 0.25-0.5. Potential for infant sedation, poor feeding. Avoid breastfeeding or use alternative therapy.
Increased clearance and volume of distribution in pregnancy may necessitate dose increase; monitor clinical response; use lowest effective dose; avoid late third trimester if possible.
Pregnancy may reduce plasma concentrations due to increased volume of distribution and enhanced clearance. Dose increases may be required, but avoid in pregnancy; if necessary, use lowest effective dose and limit duration.
ATIVAN (lorazepam) is a benzodiazepine with intermediate onset and duration; useful for status epilepticus (IV) and preoperative anxiolysis. Monitor for respiratory depression, especially when combined with opioids. Not ideal for long-term anxiety due to tolerance and dependence risk. Use with caution in elderly (increased fall risk).
CHLORDIAZACHEL is a combination of chlordiazepoxide (benzodiazepine) and clidinium (anticholinergic). Used for peptic ulcer and irritable bowel syndrome. Monitor for CNS depression and anticholinergic effects (dry mouth, blurred vision, constipation). Avoid in glaucoma, urinary retention, and myasthenia gravis. Discontinue gradually to prevent withdrawal.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking ATIVAN.,Take exactly as prescribed; do not increase dose or stop abruptly without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision.,Report any unusual mood changes, confusion, or respiratory difficulty.,This medication can be habit-forming; prolonged use may lead to dependence.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Take exactly as prescribed; do not increase dose or duration.,Avoid alcohol and other CNS depressants.,May cause drowsiness; do not drive or operate machinery until effects are known.,Report bothersome side effects like constipation, dry mouth, or blurred vision.,Do not stop suddenly; taper under medical supervision.,Inform all healthcare providers you are taking this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATIVAN vs CHLORDIAZACHEL, answered by our medical review team.
ATIVAN is a Benzodiazepine that works by Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.. CHLORDIAZACHEL is a Benzodiazepine that works by Chlordiazepoxide is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion influx, hyperpolarization of neurons, and decreased neuronal excitability. This produces anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATIVAN and CHLORDIAZACHEL depend on the specific clinical indication. These are both Benzodiazepine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATIVAN is: 2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.. The standard adult dose of CHLORDIAZACHEL is: Initial: 5-10 mg orally 3-4 times daily; for severe anxiety, up to 25 mg 4 times daily. IM: 50-100 mg initially, then 25-50 mg 3-4 times daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATIVAN and CHLORDIAZACHEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATIVAN is classified as Category C. First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avo. CHLORDIAZACHEL is classified as Category C. First trimester: Increased risk of cleft lip/palate (OR 1.8-2.5). Second/third trimester: Risk of neonatal withdrawal, hypotonia, respiratory depression. Avoid in pregnancy unless . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.